Partners HealthCare News

Anne Klibanski, MD

Anne Klibanski celebrated as CEO and 2019 Top 25 Women Leaders in Health Care by Modern Healthcare

July 12, 2019

Modern Health Care recently acknowledge the appointment of Anne Klibanski as named first female Partners HealthCare CEO and one of the magazine’s Top 25 Leaders in Healthcare for 2019. We celebrate this recognition and the work of innovative leaders across the healthcare spectrum. Celebrate Accomplishments Women Leaders in Healthcare

Read More
Anne Klibanski, MD

Partners HealthCare names Dr. Anne Klibanski as first-ever female CEO

June 26, 2019

The Partners HealthCare Board of Directors has named Anne Klibanski, MD President and Chief Executive Officer of Partners HealthCare. Dr. Klibanski becomes the first female chief executive of Partners HealthCare, the state’s largest private employer, with 75,000 employees. Dr. Klibanski was named Interim President and CEO in February. “Over the past several months, it has…

Read More

Health Providers Uncover New Revenue Streams to Advance Innovation For Patient Care

April 9, 2019

The first benchmarking study of health system efforts to generate new revenue streams evaluates a range of effective strategies to sustain overall operations, fuel innovation, and advance patient care missions. The report by Partners HealthCare and Fitzroy Health finds that successful health systems have increased operating margin as much as five points through diversification strategies.…

Read More
Anne Klibanski, MD

Partners HealthCare names Anne Klibanski, MD, as Interim President and CEO; Recognized by Modern Healthcare as one of 2019’s Top 25 Women Leaders

February 21, 2019

The Partners HealthCare Board of Directors has named Anne Klibanski, MD, Interim President and Chief Executive Officer of Partners HealthCare. Dr. Klibanski will succeed Dr. David Torchiana, who has served since March 2015 and will retire at the end of April. Earlier this month, Dr. Klibanski was recognized by Modern Healthcare as one of 2019’s…

Read More
Stories from the Stage

Partners HealthCare Chief Clinical Officer Featured in PBS’ “Stories From the Stage”

December 3, 2018

Eureka! Sometimes that moment of personal discovery comes when you least expect it. Heather Berlin came to a revelation while she dangled 40 feet above the Sydney Zoo; Gregg Meyer, MD discovered how tears could make him a better doctor; and Yari Golden-Castaño’s dream of space flight might just take her to Mars. Three storytellers,…

Read More

An Innovator’s Feast

November 7, 2018

Save the Date Westin Copley Place | Boston Wednesday, April 10, 2019 This invitation-only reception honors principal investigators and researchers who submitted invention disclosures during the calendar year 2018. The evening features a cocktail reception, live music from a PHS-member band, dinner and a keynote presentation by Alfred Sandrock, MD, PhD, Chief Medical Officer; EVP,…

Read More

Improving Hearing and Vision Leadership at Mass. Eye and Ear

November 7, 2018

Now that the Mass. Eye and Ear has officially joined Partners, leaders from both organizations are optimistic about the potential to drive new advances in treating blindness, deafness and other debilitating diseases of the head and neck. The move comes at a pivotal time as the promise of gene therapies for inherited eye and ear…

Read More

AI has arrived- Pharma Times

September 28, 2018

Artificial intelligence is poised to change the pharmaceutical and healthcare industries as it looks to streamline, speed-up and improve overall efficiency. It might still be early days but it’s a bandwagon that organisations are quickly jumping on board. According to a CB Insights report, about 86% of healthcare organisations, life science companies and med tech…

Read More

Alexion To Acquire Syntimmune

September 26, 2018

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes –…

Read More

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

September 20, 2018

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy…

Read More


August 7, 2018

Boston, Mass. – August 7, 2018 – Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced the Company has raised $50 million in Series A financing. Seed investors 5AM Ventures and New Enterprise Associates (NEA) co-led the round, and were joined by existing seed investor Partners Innovation Fund and new…

Read More

Translate Bio Announces Pricing of Initial Public Offering

August 3, 2018

Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross…

Read More

Next Chapter For Biotech? Many Say 'Convergence' With Data Science

June 13, 2018

by WBUR June 8, 2018- So far, the digital revolution has mostly been a disappointment in health care. Doctors stare at their screens instead of us. Specialists and emergency rooms still don’t have all our records. But artificial intelligence, big data analytics and deep learning are converging on health care in a big way, information…

Read More

Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-long-acting Oral Dosage Form for Chinese Market

May 8, 2018

Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China. Lyndra is developing ultra-long-acting oral therapies that free patients…

Read More

Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 6, 2018

Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced treatment of the first patient with an inherited metabolic disorder in a Phase 2 study of MGTA-456.

Read More

Denali Therapeutics prices IPO at $18 midpoint making it the largest biotech IPO of the year

December 8, 2017

Denali Therapeutics, a an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion.  

Read More

Spero Therapeutics Announces Closing of Initial Public Offering

November 7, 2017

Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions.  In addition, Spero Therapeutics, Inc. has granted the…

Read More

Spero Therapeutics Announces Pricing of Initial Public Offering

November 2, 2017

Two biotechs, Spero Therapeutics and Allena Therapeutics, are headed for the Nasdaq this morning at valuations they’d been aiming for. Their stock offerings are the latest sign of the health of the biotech IPO market, and the willingness of insiders to make sure these deals succeed. For more information, click here

Read More